Cell type-associated traits map for the [Lake_2017_FrontalCortex_Inhibitory neuron 6b][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [Lake_2017_FrontalCortex_Inhibitory neuron 6b]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
2 Hour Glucose | 2-Hour Glucose | ETC | Saxena | 2010 | NA | 15234 | 1.00e-3 | 4.62e-2 |
Age At Menarche | Age At Menarche | ETC | Perry | 2014 | NA | 182413 | 5.00e-2 | 2.02e-2 |
Aggression | Aggression | MTC | Pappa | 2015 | NA | 15668 | 5.00e-2 | 8.43e-3 |
Anorexia Nervosa | Anorexia Nervosa | MTC | Boraska | 2014 | 2907 | 14860 | 1.00e-3 | 4.37e-2 |
Anorexia Nervosa | Anorexia Nervosa | MTC | Duncan | 2017 | 3495 | 10982 | 5.00e-2 | 3.17e-2 |
Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 1.00e-5 | 3.97e-2 |
BMI | Body Mass Index | MTC | Yang | 2012 | NA | 133154 | 1.00e-3 | 4.90e-2 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 2.88e-3 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 5.00e-2 | 3.03e-3 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 3.15e-2 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-2 | 3.15e-2 |
Gait Speed | Gait Speed | MTC | Ben-Avraham | 2017 | NA | 31478 | 5.00e-2 | 6.45e-3 |
Gait Speed | Gait Speed | MTC | Ben-Avraham | 2017 | NA | 31478 | 1.00e-2 | 1.72e-3 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 5.00e-2 | 1.87e-2 |
Insomnia | Insomnia | MTC | Hammerschlag | 2017 | 12863 | 40776 | 5.00e-2 | 2.48e-2 |
Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 5.00e-2 | 2.63e-3 |
Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 1.00e-2 | 3.78e-3 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 5.00e-2 | 4.20e-2 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 1.00e-3 | 3.95e-2 |
MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 5.00e-2 | 7.66e-3 |
MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 1.00e-2 | 2.37e-2 |
MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 1.00e-3 | 4.37e-3 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 5.00e-2 | 5.50e-5 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-2 | 3.70e-5 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-3 | 2.79e-6 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-5 | 4.09e-2 |
Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 2.70e-2 |
Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 6.59e-3 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-2 | 6.09e-5 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-3 | 9.92e-5 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-4 | 7.74e-4 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-5 | 3.78e-4 |
Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 5.00e-2 | 3.31e-2 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 5.00e-2 | 4.06e-3 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 1.00e-2 | 4.50e-2 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 1.82e-4 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 1.00e-3 | 4.37e-2 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 5.00e-2 | 4.57e-3 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 1.00e-4 | 2.17e-2 |
Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 5.00e-2 | 3.53e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 5.00e-2 | 1.58e-3 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 5.00e-2 | 1.29e-2 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 5.00e-2 | 1.58e-3 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 1.00e-2 | 1.21e-2 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 1.00e-3 | 3.23e-3 |
Anthropometric Extremes | Extreme BMI | MTC | Berndt | 2013 | 7962 | 8106 | 5.00e-2 | 4.42e-3 |
Anthropometric Extremes | Extreme BMI | MTC | Berndt | 2013 | 7962 | 8106 | 1.00e-2 | 2.06e-2 |
Anthropometric Extremes | Obesity Class 2 | MTC | Berndt | 2013 | 9889 | 65840 | 5.00e-2 | 4.23e-2 |
Anthropometric Extremes | Overweight | MTC | Berndt | 2013 | 93015 | 65840 | 1.00e-3 | 2.68e-2 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 5.00e-2 | 3.99e-2 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-2 | 4.07e-3 |
Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 5.00e-2 | 2.30e-2 |
Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-2 | 1.21e-2 |
Anxiety | Anxiety Dichotomous | MTC | Otowa | 2016 | 7016 | 14745 | 5.00e-2 | 1.85e-2 |
Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 5.00e-2 | 3.26e-2 |
Blood Cells | Basophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.78e-2 |
Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.83e-2 |
Blood Cells | Mean Corpuscular Hemoglobin Concentration | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.51e-3 |
BMI Age Stratified | BMI Women Age Over 50 | MTC | Winkler | 2015 | NA | 106622 | 5.00e-2 | 3.10e-2 |
BMI | BMI European | ETC | Locke | 2015 | NA | 234069 | 1.00e-4 | 3.39e-2 |
BMI | BMI European Men | MTC | Locke | 2015 | NA | 104666 | 1.00e-3 | 4.24e-2 |
BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.94e-2 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 3.93e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.84e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.76e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.89e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 4.27e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 5.87e-3 |
Bone Mineral Density | Femoral Neck Bone Mineral Density All | MTC | Estrada | 2012 | NA | 32961 | 1.00e-4 | 1.45e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density All | MTC | Estrada | 2012 | NA | 32961 | 1.00e-5 | 1.55e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 32961 | 1.00e-3 | 4.29e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 32961 | 1.00e-5 | 5.95e-3 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-4 | 1.29e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-5 | 2.90e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 30 to 45 | MTC | Medina-Gomez | 2018 | NA | 10062 | 1.00e-3 | 1.30e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 30 to 45 | MTC | Medina-Gomez | 2018 | NA | 10062 | 1.00e-4 | 6.59e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 60 And More | MTC | Medina-Gomez | 2018 | NA | 22504 | 5.00e-2 | 1.65e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 60 And More | MTC | Medina-Gomez | 2018 | NA | 22504 | 1.00e-2 | 1.47e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 60 And More | MTC | Medina-Gomez | 2018 | NA | 22504 | 1.00e-5 | 1.92e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-5 | 3.51e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density Under 15 | MTC | Medina-Gomez | 2018 | NA | 11807 | 1.00e-4 | 3.59e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 1.00e-5 | 4.09e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-2 | 4.94e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 8.06e-4 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-2 | 3.76e-2 |
Cognitive Functions | Memory | MTC | Davies | 2016 | NA | 112067 | 5.00e-2 | 4.49e-2 |
Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 5.00e-2 | 1.88e-2 |
Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 1.00e-2 | 2.44e-2 |
Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 2 | MTC | Bustamante | 2016 | 990 | 5243 | 5.00e-2 | 2.82e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 3684 | 5.00e-2 | 1.03e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 5.00e-2 | 4.59e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 1.00e-3 | 4.09e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 5.00e-2 | 2.17e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 2.46e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 5.00e-2 | 4.78e-2 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-2 | 4.28e-4 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 8.01e-3 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 3.18e-3 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 1.05e-3 |
Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.60e-2 |
Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 9.54e-4 |
Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.27e-4 |
Facial Shape | Mod14 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.56e-2 |
Facial Shape | Mod16 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.04e-2 |
Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.99e-2 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.61e-2 |
Facial Shape | Mod2 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.03e-2 |
Facial Shape | Mod21 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 8.47e-3 |
Facial Shape | Mod21 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.50e-3 |
Facial Shape | Mod23 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.27e-2 |
Facial Shape | Mod24 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.21e-2 |
Facial Shape | Mod24 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.13e-2 |
Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.09e-2 |
Facial Shape | Mod27 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 6.93e-3 |
Facial Shape | Mod27 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.01e-3 |
Facial Shape | Mod29 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.27e-2 |
Facial Shape | Mod3 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.68e-2 |
Facial Shape | Mod31 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.49e-3 |
Facial Shape | Mod32 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.82e-2 |
Facial Shape | Mod32 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.06e-2 |
Facial Shape | Mod33 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 7.07e-3 |
Facial Shape | Mod39 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.93e-2 |
Facial Shape | Mod43 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.50e-3 |
Facial Shape | Mod44 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.58e-2 |
Facial Shape | Mod49 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.96e-2 |
Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.94e-2 |
Facial Shape | Mod54 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 3.41e-2 |
Facial Shape | Mod62 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.09e-2 |
Facial Shape | Mod62 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.17e-2 |
Facial Shape | Mod7 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.59e-3 |
Facial Shape | Mod7 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.86e-2 |
Facial Shape | Mod7 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 7.00e-4 |
Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 2.65e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 1.00e-3 | 2.30e-2 |
Gestational Weight Gain | Late Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 8641 | 5.00e-2 | 4.55e-2 |
Glucose Stimulated Insulin Secretion | AUC Insulin | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 5.19e-4 |
Glucose Stimulated Insulin Secretion | AUC Insulin | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 9.49e-3 |
Glucose Stimulated Insulin Secretion | AUC Insulin Over AUC Glucose | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.04e-2 |
Glucose Stimulated Insulin Secretion | AUC Insulin Over AUC Glucose | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 8.67e-3 |
Glucose Stimulated Insulin Secretion | Incremental Insulin At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 3.97e-2 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.24e-2 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 1.08e-3 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes Corrected For BMI | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.88e-2 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes Corrected For BMI | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 2.03e-2 |
Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 5.88e-3 |
Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 5.00e-2 | 1.56e-3 |
Glycemic Traits BMI Corrected | Fasting Insulin | MTC | Manning | 2012 | NA | 51750 | 5.00e-2 | 2.20e-2 |
Glycemic Traits | Fasting Insulin | ETC | Dupuis | 2010 | NA | 38238 | 1.00e-2 | 4.18e-2 |
Glycemic Traits | HOMA IR | MTC | Dupuis | 2010 | NA | 37037 | 5.00e-2 | 1.32e-2 |
Glycemic Traits | HOMA IR | MTC | Dupuis | 2010 | NA | 37037 | 1.00e-2 | 1.99e-2 |
Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 1.64e-3 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 2.15e-2 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 3.03e-2 |
Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 1.00e-2 | 4.79e-2 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 5.00e-2 | 4.93e-2 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-2 | 1.62e-2 |
Kidney Function | Rapid Decline | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 3.80e-2 |
Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 5.00e-2 | 1.84e-2 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 9.64e-3 |
Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 2.58e-4 |
Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 1.00e-2 | 3.03e-2 |
Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 3.22e-2 |
Reproductive Behavior | Age First Birth Male | MTC | Barban | 2016 | NA | 48408 | 5.00e-2 | 4.31e-2 |
Reproductive Behavior | Age First Birth Pooled | ETC | Barban | 2016 | NA | 238064 | 1.00e-2 | 3.84e-2 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-3 | 4.86e-2 |
Smoking | Current Vs Former Discrete | MTC | Furberg | 2010 | 20619 | 15226 | 5.00e-2 | 1.06e-2 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 3.82e-2 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 1.00e-2 | 1.49e-2 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-3 | 4.37e-2 |
Waist Format 1 | Hip Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 2.44e-2 |
Waist Format 1 | Waist Circumference European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 2.54e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 3.39e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 3.17e-2 |
BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 5.00e-2 | 3.30e-3 |
BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 1.00e-2 | 1.33e-2 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-2 | 2.27e-5 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-3 | 5.36e-3 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-2 | 5.52e-6 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-3 | 6.97e-5 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-4 | 1.45e-5 |
Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 5.00e-2 | 6.44e-4 |
Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 5.00e-2 | 2.34e-2 |
Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 1.00e-2 | 3.04e-2 |
Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 5.00e-2 | 8.44e-3 |
Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-2 | 1.05e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 2.78e-2 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 2.90e-2 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 5.00e-2 | 7.48e-4 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 1.00e-2 | 3.24e-2 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 1.00e-4 | 4.86e-2 |
Sleep | Sleep time to least active 5 hours | ETC | Jones | 2019 | NA | 85205 | 1.00e-3 | 2.71e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 3.11e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.90e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-4 | 2.03e-2 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 8.80e-6 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-2 | 8.89e-4 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-3 | 8.23e-4 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-4 | 6.50e-4 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-5 | 1.47e-3 |
Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 1.26e-3 |
Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 1.26e-3 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 5.00e-2 | 4.54e-2 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 1.00e-2 | 4.24e-3 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 1.00e-4 | 7.97e-3 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 5.00e-2 | 4.77e-2 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-3 | 3.92e-2 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-4 | 4.54e-2 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-5 | 1.38e-2 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-2 | 3.53e-6 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-3 | 2.65e-5 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-4 | 2.18e-3 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-5 | 1.45e-2 |
Glycine level | Glycine level | ETC | Wittemans | 2019 | NA | 80003 | 1.00e-4 | 3.14e-2 |
Glycine level | Glycine level | ETC | Wittemans | 2019 | NA | 80003 | 1.00e-5 | 2.70e-2 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 5.00e-2 | 1.53e-4 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-2 | 5.88e-4 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-3 | 2.18e-3 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-4 | 1.39e-2 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-5 | 1.08e-2 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-3 | 6.58e-5 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-4 | 1.82e-4 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-5 | 2.80e-4 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-2 | 7.17e-6 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-3 | 1.26e-4 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-4 | 5.86e-4 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-5 | 4.94e-4 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 4.72e-2 |
Body fat distribution | Body fat distribution-arm-fat-ratio-female | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 1.98e-2 |
Body fat distribution | Body fat distribution-arm-fat-ratio-female | ETC | Andersen | 2019 | NA | 116138 | 1.00e-5 | 2.65e-2 |
Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 5.00e-2 | 2.93e-2 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-2 | 2.25e-3 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-3 | 5.14e-3 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-4 | 4.94e-3 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 5.00e-2 | 3.14e-6 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-2 | 1.21e-4 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-3 | 4.55e-2 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-4 | 3.84e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 5.00e-2 | 1.24e-4 |
Smoking | Smoking behaviour, cigarettes smoked per day | ETC | Liua | 2019 | NA | 377334 | 1.00e-4 | 3.00e-2 |
Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 1.00e-3 | 9.90e-3 |
Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 1.00e-4 | 8.59e-3 |
Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 1.00e-5 | 1.44e-2 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 5.00e-2 | 7.43e-4 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-2 | 1.64e-3 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-3 | 1.66e-3 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-4 | 1.72e-2 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-5 | 2.22e-2 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 5.00e-2 | 1.31e-3 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-2 | 7.70e-5 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-3 | 5.78e-5 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-4 | 2.70e-3 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-5 | 3.13e-2 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-2 | 1.69e-3 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-3 | 1.78e-2 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-4 | 4.91e-2 |
Postburn scar height | Postburn scar height | ETC | Wallace | 2018 | NA | 665 | 5.00e-2 | 3.90e-2 |
Postburn scar pliability | Postburn scar pliability | ETC | Wallace | 2018 | NA | 665 | 5.00e-2 | 4.25e-2 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 3.85e-3 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 9.60e-3 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 8.32e-3 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 7.67e-3 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 8.86e-3 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 1.83e-2 |
Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 5.74e-3 |
Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 1.00e-2 | 4.02e-2 |
Hippocampal volume | Total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.58e-2 |
Hippocampal volume | Total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-4 | 4.90e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.94e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 1.17e-2 |
Hippocampal volume | Hippocampal tail volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.48e-2 |
Hippocampal volume | Hippocampal subfield CA4 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 2.38e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.92e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 2.88e-2 |
ACR | Urinary albumin to creatinine ratio | ETC | Zanetti | 2019 | NA | 218759 | 5.00e-2 | 3.69e-2 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 5.00e-2 | 1.76e-4 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-2 | 1.46e-2 |
AUDIT-C | Alcohol-Use-Disorder-Identification-Test-Consumption | ETC | Kranzler | 2019 | NA | 200680 | 5.00e-2 | 4.04e-2 |
AUDIT-C | Alcohol-Use-Disorder-Identification-Test-Consumption | ETC | Kranzler | 2019 | NA | 200680 | 1.00e-2 | 1.25e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 5.58e-3 |
Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 5.00e-2 | 4.39e-2 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 5.00e-2 | 4.48e-2 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-2 | 2.21e-2 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 5.00e-2 | 3.05e-3 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 1.00e-2 | 2.31e-2 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 1.21e-2 |
Renal cell carcinoma | Renal cell carcinoma female | ETC | Laskar RS | 2019 | 1,992 | 3,095 | 5.00e-2 | 1.04e-2 |
Renal cell carcinoma | Renal cell carcinoma female | ETC | Laskar RS | 2019 | 1,992 | 3,095 | 1.00e-2 | 3.02e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 1.26e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT3) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-3 | 3.87e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 1.14e-2 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 5.00e-2 | 4.52e-2 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 9,844 | 20,403 | 5.00e-2 | 2.02e-2 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-2 | 1.10e-2 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-3 | 3.83e-2 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-4 | 1.15e-2 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-5 | 1.73e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-2 | 2.50e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-3 | 1.46e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-4 | 2.69e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-5 | 2.79e-2 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 5.00e-2 | 2.25e-2 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-2 | 3.50e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 5.00e-2 | 3.24e-2 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 5.00e-2 | 2.02e-3 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 2.13e-2 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-3 | 1.23e-2 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 2.42e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-2 | 9.40e-5 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-3 | 3.34e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-4 | 1.85e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-2 | 2.29e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-3 | 4.01e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-4 | 2.38e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-3 | 2.81e-5 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-4 | 8.65e-5 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-5 | 6.37e-4 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-2 | 2.07e-3 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-3 | 2.54e-2 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-4 | 3.43e-2 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-5 | 3.55e-2 |
Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-5 | 4.68e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 3.42e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-4 | 4.95e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-4 | 2.50e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-5 | 4.42e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-2 | 3.45e-5 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-3 | 1.00e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 374,756 | 1.00e-4 | 2.65e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 374,756 | 1.00e-5 | 4.57e-2 |
Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-2 | 4.82e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 434,794 | 1.00e-3 | 9.37e-5 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 434,794 | 1.00e-4 | 4.06e-3 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 434,794 | 1.00e-5 | 1.41e-2 |
AD | Alzheimer's disease | ETC | Moreno-Grau S | 2019 | 4,120 | 3,289 | 5.00e-2 | 3.56e-2 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 5.00e-2 | 4.21e-2 |
Heel bone mineral Density | Heel bone mineral density variance | ETC | Wang H | 2019 | NA | 197,261 | 5.00e-2 | 2.29e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 5.00e-2 | 2.67e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-2 | 8.06e-3 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-3 | 9.40e-3 |
BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 5.00e-2 | 4.46e-3 |
BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 1.00e-2 | 1.17e-2 |
Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 5.00e-2 | 3.17e-2 |
Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-2 | 2.95e-3 |
Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-4 | 6.59e-3 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-3 | 2.29e-3 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-3 | 1.11e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-4 | 6.13e-3 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-3 | 3.93e-2 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-4 | 6.44e-3 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-2 | 1.12e-2 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 5.00e-2 | 6.66e-3 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-2 | 1.58e-3 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-3 | 2.02e-3 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-4 | 1.30e-2 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.60e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.27e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 4.16e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.85e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.10e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 7.65e-3 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.98e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.23e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 9.86e-3 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.75e-4 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 9.20e-3 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 3.03e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.30e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 4.88e-5 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 3.58e-2 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 6.95e-3 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.03e-2 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.39e-2 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.80e-2 |
IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.54e-2 |
IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.20e-2 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.38e-3 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.44e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.96e-2 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 5.00e-2 | 1.03e-3 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 5.00e-2 | 7.44e-3 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-2 | 2.27e-2 |
Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 5.00e-2 | 1.03e-2 |
Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-2 | 3.36e-2 |
COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 5.00e-2 | 1.67e-2 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis II) | ETC | Ellinghaus D | 2020 | 1610 | 2180 | 5.00e-2 | 2.45e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.